Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.

ABSTRACT:

Purpose

Chronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary intervention (PCI). Whether the presence of CYP2C19 loss of function (LOF) alleles modifies this risk, and whether a genotype-guided (GG) escalation of P2Y₁₂ inhibitor therapy post PCI is safe in this population is unclear.

Methods

This was a post hoc analysis of randomized patients in TAILOR PCI. Patients were divided into two groups based on estimated glomerular filtration rate (eGFR) threshold of < 60 ml/min/1.73 m² for CKD (n = 539) and non-CKD (n = 4276). The aggregate of cardiovascular death, stroke, myocardial infarction, stent thrombosis, and severe recurrent coronary ischemia at 12-months post-PCI was

SUBMITTER: Mathew RO 

PROVIDER: S-EPMC10225474 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature